Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,Whats New LAL-D

    Launch of LAL-D Knowledge Centre

    A new educational resource on lysosomal acid lipase deficiency is
    now available to epgonline.org users. Content highlights include latest
    disease awareness facts and statistics, important treatment information and
    a video channel comprising expert discussions on topics such
    as diagnostic approach and current prognosis.

  • ,CSU news case studies 2016

    Updates to the Chronic Spontaneous
    Urticaria Knowledge Centre

    Case studies from urticaria experts Professor Christian Vestergaard
    and Professor Torsten Zuberbier have been added to the ‘Case Studies
    section of the Chronic Spontaneous Urticaria Knowledge Centre.
    Additionally, this resource has been updated with information
    on the TARGET My Hives app and refreshed with a whole new look and feel.

  • ,OAC Reversal Whats New 2

    Launch of Oral Anticoagulation Reversal Knowledge Centre

    This new resource provides healthcare professionals with accurate information on the approaches
    to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding,
    or require surgery. View illustrated and referenced sections on management of bleeding, oral
    anticoagulants, symposium highlights, key publications commentary and more. This resource is
    developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with
    content provided by CSL Behring.

    This resource is not intended for healthcare professionals outside Europe.

  • ,Hypogonadism Relaunch Whats New

    Launch of updated Hypogonadism Knowledge Centre

    Our Hypogonadism Knowledge Centre contains important disease awareness
    information to support healthcare professionals in the current best practice
    treatment and management of male hypogonadism and is available to access free of
    charge. Sections cover epidemiology, pathophysiology, signs and symptoms, treatment
    options, as well as useful resources and a regularly updated publications digest.

    G.MKT.GM.MH.01.2016.0364

  • ,Cystic Fibrosis Knowledge Centre

    Launch of the Cystic Fibrosis Knowledge Centre

    This new resource has been developed to support healthcare professionals
    in the treatment of patients with cystic fibrosis (CF).
    It contains a host of clinical information including a disease awareness section,
    emerging and supportive therapeutic options and current best practice
    based on recently updated guidelines by the
    European Cystic Fibrosis Society (ECFS).

Latest News

BAF 312 (siponimod) reports Phase III results in treatment of secondary progressive multiple sclerosis.-Novartis

26-Aug-2016

Novartis announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF 312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability ...

NEJM publishes CASTOR study of daratumumab, bortezomib, and dexamethasone for Multiple Myeloma- Genmab A/S + Janssen Biotech

26-Aug-2016

Genmab A/S announced that The New England Journal of Medicine has published data from the Phase III CASTOR (MMY3004) study of daratumumab. The CASTOR data were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting and ...

Complete Response Letter from FDA for Parsabiv (etelcalcetide), a proposed treatment for secondary hyperparathyroidism.-Amgen

26-Aug-2016

Amgen announced that the FDA has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on ...

NICE positive for use of Eylea (aflibercept) to treat macular oedema secondary to branch retinal vein occlusion (BRVO)- Bayer HealthCare

26-Aug-2016

The National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) from Bayer HealthCare as a cost-effective first-line treatment option for adults with visual impairment due to macular oedema secondary to branch ...

Buprenorphine sublingual spray meets primary endpoint in phase III trial for moderate to severe postoperative pain - Insys Therapeutics

26-Aug-2016

Insys Therapeutics has reported that the Phase III trial for the buprenorphine sublingual spray met its primary endpoint for moderate to severe pain. The trial was a multicenter, randomized, double-blind, multiple-dose, placebo-controlled study ...

Mallinckrodt sells its nuclear imaging business to IBA Molecular for $690 million.

26-Aug-2016

Mallinckrodt plc, a leading specialty pharmaceutical company, announced that it has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular, for approximately $690 million before tax impacts, ...

FDA accepts an NDA from Clovis Oncology for rucaparib to treat advanced ovarian cancer in patients with deleterious BRCA-mutated tumors.

25-Aug-2016

Clovis Oncology, Inc. announced that the FDA has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February ...

Recent Updates

Drugs

Clinical Guidelines

2016 European Guidelines on cardiovascular disease prevention in clinical practice

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

EASL Clinical Practice Guidelines on the management of benign liver tumours

EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones

Medical Journals

Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.

Hypothyroidism and obesity: An intriguing link.

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.

Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors